Peroneal nerve paralysis

Summary

Peroneal nerve paralysis (MONDO:0006903) is a disease. A subtype of peripheral nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peroneal nerve paralysis
Mondo ID	MONDO:0006903
EFO	EFO:1001102
DOID	DOID:6925
NCIT	C27061
SNOMED CT	399088004
UMLS	C0270810
MedGen	78733
MedDRA	10033828
Is cancer (heuristic)	no

Also known as: nerve palsy, peroneal · palsy, peroneal nerve

Disease family

This is a subtype of peripheral nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peroneal nerve paralysis

Related subtypes (17): autoimmune disorder of peripheral nervous system, autonomic nervous system disorder, peripheral nervous system neoplasm, vestibulocochlear nerve disorder, hypoglossal nerve disorder, facial nerve disorder, neuroma, accessory nerve disorder, glossopharyngeal nerve disorder, olfactory nerve disorder, radiculopathy, trigeminal nerve disorder, third cranial nerve disorder, peripheral neuropathy, cauda equina syndrome, trochlear nerve disorder, abducens nerve disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.